Skip to content
Screener

Eton Pharmaceuticals, Inc. ETON Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$22.5MBeat by $2.0M
EPS-$0.07Miss by $0.23
Revenue estimate$20.5M
EPS estimate$0.16

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$42.0M
EPS estimate$0.34

Financials

Q3 2025

Income statement

See full
Revenue$22.5M+118%
Gross profit$7.9M+24.6%
Operating income-$1.4M-368%
Net income-$1.9M-407%
EPS (diluted)-$0.07-450%

Balance sheet

See full
Cash & equivalents$37.1M+83.2%
Total debt$30.9M+614%
Total equity$23.1M+44.7%
Total assets$104.5M+192%

Cash flow

See full
Operating cash flow$12.0M+307%
CapEx$284.0K—
Free cash flow$11.7M+298%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$582.75M+276%
Enterprise value$576.5M+315%
P/S8.3×+3.8×

Profitability

See full
Gross margin51.4%-7.9pp
Net margin-9.5%-2.7pp

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity1.3×+1.1×
Current ratio1.6×+0.1×

FAQ

When did Eton Pharmaceuticals, Inc. report Q3 2025 earnings?
Eton Pharmaceuticals, Inc. (ETON) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Eton Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Eton Pharmaceuticals, Inc. reported revenue of $22.5M and eps of $-0.07 for Q3 2025.
Did Eton Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $20.5M by $2.0M. EPS missed the consensus estimate of $0.16 by $0.23.
How did Eton Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 117.5% from $10.3M a year earlier.
Where can I find Eton Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-033616) and the 10-Q periodic report (0001437749-25-033619) directly on SEC EDGAR. The filing index links above go to sec.gov.